Switzerland
Manufacturer/ Producer
Ever since our foundation, we have been based in Flurlingen - Schaffhausen, Switzerland At the beginning of QMEDICS’ existence, we offered only contract R&D and manufacturing of medical devices and produced for other big companies stents and balloon dilatation catheters. QMEDICS contract manufacturing services consistently deliver quality assured products that meet tight specifications. Our extensive expertise and knowledge of international requirements helps to assure your product will be compliant with the harmonized standards and regional requirements. Our goal is to deliver customized products and personalized services, to help our customers to achieve their goals in a timely, efficient, and cost-effective manner. Three years ago, Qmedics re-organized and started as a legal manufacturer with our own portfolio on top of the contracted manufacturing. We developed a new stent strategy for peripheral arterial stenting, more adapted to the characteristics of the lesions and the movability of the arteries. It is our believe that a modern stent design to perform well in increasingly demanding clinical scenarios lies in different stent properties to improve long term clinical outcomes. We certainly move away from the idea of “one fits all” strategy. All our stents are of Nitinol, self expanding and are manufactured up to a length of 200 mm with an excellent scaffolding , high patency and resistant to kinking and compression
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for a quoteCreate one request and get multiple quotes form verified suppliers.